Home » Stocks » SMMT

Summit Therapeutics PLC (SMMT)

Stock Price: $4.70 USD -0.01 (-0.21%)
Updated December 3, 9:47 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 315.99M
Revenue (ttm) 22.09M
Net Income (ttm) -50.29M
Shares Out 335.89M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $4.70
Previous Close $4.71
Change ($) -0.01
Change (%) -0.21%
Day's Open 4.74
Day's Range 4.68 - 4.74
Day's Volume 9,199
52-Week Range 3.25 - 4.91

More Stats

Market Cap 315.99M
Enterprise Value 295.27M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 335.89M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.26
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 57,968
Short Ratio 0.44
Short % of Float n/a
Beta 0.59
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 14.30
PB Ratio 10.69
Revenue 22.09M
Operating Income n/a
Net Income -50.29M
Free Cash Flow n/a
Net Cash 20.72M
Net Cash / Share 0.31
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -36.13%
ROE n/a
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

Current: $4.70
Target: 4.00
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial numbers in millions GBP.

Financial Overview

Revenue Growth-247.99%436.46%-----
Gross Profit-53.7715.452.88----
Operating Income-3.34-32.29-31.07-25.43-15.29-8.39-5.72
Net Income-9.36-25.20-26.71-25.17-14.23-7.62-5.28
Shares Outstanding16073.5661.8461.2941.1258.3758.37-
Earnings Per Share-0.11-0.39-0.44-0.43-0.36-0.38-0.34
Operating Cash Flow-25.98-33.33-18.1815.18-21.48-14.58-7.34-3.98
Capital Expenditures-0.27-0.15-0.45-0.10-0.08-0.040.08-0.04
Free Cash Flow-26.25-33.48-18.6315.08-21.56-14.63-7.26-4.03
Cash & Equivalents63.8433.5725.1335.0820.3814.082.54-
Total Debt0.891.265.477.406.292.69--
Net Cash / Debt62.9532.3219.6627.6814.0911.392.54-
Book Value77.2453.17-3.94-4.3720.1016.205.95-
Numbers in millions GBP, except per-share numbers.

Company Profile

Company Details

Full Name Summit Therapeutics PLC
Employees 70

Stock Information

Ticker Symbol SMMT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SMMT


Summit Therapeutics, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. Summit Therapeutics Inc. was founded in 2003 and is based in Cambridge, Massachusetts.